This proposal aims to determine a new mechanism regulating androgen receptor (AR) function in prostate cancer cellular growth. Prostate cancer progression correlates with increased activity/expression of AR, Akt1, c-jun and cyclin D1 and reduced histone acetylation. We showed the AR is acetylated at a conserved motif, that this AR acetylation site promotes cellular growth by regulating recruitment of HDAC/NCoR/Smad complexes to the promoters of a subset of cell-cycle regulatory genes. We showed that 1. AR acetylation and phosphorylation are linked, 2. SirT1 expression and function are regulated by dihydrotestosterone (DHT) and metabolism 3. AR is repressed by the NAD-dependent histone deacetylases (SirT1), and 4. AR acetylation site is a target of Akt/c-jun/cyclin D1/Sirt1. The proposed studies will determine in vivo the functional significance of Akt/c-jun/cyclin D1/Sirt1 in AR function.
Aim 1. Determine in vivo significance of AR regulation by Akt1 and cyclin D1. AR expression and function are enhanced by Akt and inhibited by cyclin D1 in cultured tumor cell lines. Akt1-/- and cyclin D1-/- prostate epithelial cells will be examined in 2D and 3D culture and in the prostate in vivo.
Aim 2. Determine in vivo significance of AR regulation by c-jun and SirT1. c-jun enhances and SirT1 represses AR function in cultured prostate cancer cells. The role of c-jun and SirT1 in regulating AR function in vivo is unknown due to the embryonic or perinatal lethality of genetic deletion. We will determine the role of c- jun and Sirt1 in AR signaling using c-junfl/fl and SirT1fl/fl mice Aim 3. Determine functional significance of Sirt1 in prostate cellular growth in vivo. The AR acetylation site functions as a growth switch of the AR in prostate cancer cells in culture and in nude mice. Sirt1 inhibits AR-mediated prostate cellular growth. We will determine the functional significance of Sirt1 in prostate growth in vivo using SirT1fl/fl mice and Probasin CRE mice. Prostate cancer is the most frequently diagnosed cancer in men in the United States and the second leading cause of male cancer deaths. Prostate cancer unresponsive to therapy emerges in patients. These three integrated Aims will determine the role of an Akt/c-jun/cyclin D1/SirT1 pathway in AR function in vivo and thereby identify key new therapeutic options.

Public Health Relevance

The mechanisms governing androgen ablation therapy resistance of prostate cancer involves hyperactivation of the AR. A subset of key genes correlate with prostate cancer outcome and/or have been shown to regulate AR activity in prostate cancer cells in tissue culture (Akt1, c-Jun, cyclin D1, Sirt1), however, the role of these key genes in regulating AR function in vivo is not known, therefore, we have generated genetic deletion models in the mouse. As our studies show acetylation of the AR governs the growth properties of the AR in human prostate cancer cells and the AR acetylation site is a key target through which these genes (Akt1, c-Jun, cyclin D1, Sirt1) regulate the AR, we have developed new prostate cancer cell lines to conduct mechanistic studies of the regulation of AR acetylation by these target genes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA086072-11
Application #
8446156
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Snyderwine, Elizabeth G
Project Start
2000-04-01
Project End
2014-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
11
Fiscal Year
2013
Total Cost
$214,812
Indirect Cost
$103,113
Name
Thomas Jefferson University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Casimiro, Mathew C; Di Sante, Gabriele; Di Rocco, Agnese et al. (2017) Cyclin D1 Restrains Oncogene-Induced Autophagy by Regulating the AMPK-LKB1 Signaling Axis. Cancer Res 77:3391-3405
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Ju, Xiaoming; Jiao, Xuanmao; Ertel, Adam et al. (2016) v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. Cancer Res 76:6723-6734
Jiao, Xuanmao; Rizvanov, Albert A; Cristofanilli, Massimo et al. (2016) Breast Cancer Stem Cell Isolation. Methods Mol Biol 1406:121-35
Zhao, Qian; Deng, Shengqiong; Wang, Guangxue et al. (2016) A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer. Oncotarget 7:21865-74
Casimiro, Mathew C; Di Sante, Gabriele; Ju, Xiaoming et al. (2016) Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells. Cancer Res 76:329-38
Di Sante, Gabriele; Pestell, Timothy G; Casimiro, Mathew C et al. (2015) Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria. Am J Pathol 185:266-79
Lamb, Rebecca; Ozsvari, Bela; Bonuccelli, Gloria et al. (2015) Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells. Oncotarget 6:21892-905
Trerotola, Marco; Ganguly, Kirat K; Fazli, Ladan et al. (2015) Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget 6:14318-28
Chen, Ke; Wu, Kongming; Jiao, Xuanmao et al. (2015) The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module. Cancer Res 75:1992-2004

Showing the most recent 10 out of 189 publications